Solutions

Online Inquiry

* Your Name

* Phone Number

* E-mail Address

* Services Interested

Project Description

Please note that we are a research service provider, not a pharmacy or clinic, so we are unable to see patients and do not offer diagnostic and treatment services for individuals.

Orbital Lymphoma

Orbital Lymphoma is a type of wildly incurable lymphoma that develops outside of lymphatic systems. Protheragen offers complete coverage on orbital lymphoma therapeutic development services by assisting with everything from target identification, validation, and even preclinical development.

Introduction to Orbital Lymphoma

Orbital lymphoma is a rare type of non-Hodgkin's lymphoma (NHL) that primarily targets the orbital region which includes the conjunctiva, eyelids, lacrimal glands and ocular muscles. Orbital lymphoma represents about 1% of all NHL cases but is the most common primary malignant tumor of the orbit of the eye in people over 60 years of age. Most cases of orbital lymphoma are extranodal marginal zone B-cell lymphomas of mucosa associated lymphoid tissue (MALT) type which are slow growing and present with nonspecific signs and symptoms of orbital swelling, pain, and restricted movement of the eyes.

Age-standardized incidence rates of orbital lymphoma in different states of the United States.

Fig.1 Age-standardized incidence rates in diferent U.S. states. (Alfaar A. S., et al., 2024)

Diagnostic Methods for Orbital Lymphoma

Histopathological Examination

Combining immunohistochemistry and histopathological techniques in the analysis of biopsy samples is critical in determining the subtype of lymphoma. Indolent versus aggressive forms of the disease are distinguished using generally accepted markers CD20, CD45, and Ki-67.

Molecular Diagnostics

Specific genetic markers relevant to certain subtypes of lymphoma can be detected using flow cytometry and polymerase chain reaction techniques. For example, the identification of monoclonal immunoglobulin light chains can be achieved by immunohistochemical staining or flow cytometry, which is helpful for stratified therapies.

Therapeutics Development for Orbital Lymphoma

Immunotherapy
In relapsed or refractor cases of orbital lymphoma, monoclonal antibodies like rituximab have shown promise. Rituximab, which has been used solo as well as in conjunction with chemotherapy, works on CD20 antigen present on B-lymphocytes. Small studies have also been done on infusion of rituximab into the lesion, where several cases achieved complete remission.
Targeted Therapies
Focused therapies such as Chimeric Antigen Receptor (CAR) T cell therapy are being explored as therapeutics options for refractory cases of orbital lymphoma. CAR-T cell therapy requires the modification of a patient's T cells so that they express a CAR that binds to certain antigens on the surface of the cancer cells. This method has demonstrated high response rates and long-lasting remission periods during human testing.

Our Services

Recognizing that each client's requirements are distinct, Protheragen provides services that are bespoke to particular research and development needs. Our team collaborates with clients to craft and execute proprietary approaches for the development of diagnostics and therapeutics.

Diagnostics Development

Karyotype Analysis Service
Omics Analysis Service
Biomarker Development Service
Artificial Intelligence Service

Therapeutic Development

Small Molecule Drug
Cell Therapy
Gene Therapy
Therapeutic Antibody
Therapeutic Peptide
Therapeutic Protein

Preclinical Research

Pharmacodynamics Study Services
Pharmacokinetics Study Services
Drug Safety Evaluation Services

Disease Models

Pfeiffer Cell Line -Derived BALB/c Nude Models
Pfeiffer Cell Line-Derived NOD/SCID Models
Canine Spontaneous Lymphoma Models
Genetic Manipulation Zebrafish Models

Protheragen's preclinical research services are designed to accelerate the development of new therapies for orbital lymphoma. We provide a range of in vitro and in vivo models, including cell-based assays, 3D tumor spheroids, and animal models, to evaluate the efficacy and safety of potential therapeutics. If you are interested in our services, please feel free to contact us.

References

Alfaar, Ahmad Samir, et al. "Declining incidence and improving survival of ocular and orbital lymphomas in the US between 1995 and 2018." Scientific Reports 14.1 (2024): 7886.
Eckardt, André M., et al. "Orbital lymphoma: diagnostic approach and treatment outcome." World journal of surgical oncology 11 (2013): 1-7.